drug targets

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) 27.9% HIGHER; announced the publication of an article that reviews and discusses the company's seliciclib (CYC202 or R-roscovitine) product candidate, an orally available inhibitor of multiple cyclin-dependent kinases and its mechanism of action.

The peer-reviewed article, "Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs" was published in the online edition of Current Drug Targets.

Magal Security Systems (Nasdaq: MAGS) 22.2% HIGHER; the stock seems to be breaking out on technicals today.

Compugen Ltd. (NASDAQ: CGEN) 63% HIGHER; announced today that it has signed a collaboration agreement with Pfizer for the predictive discovery by Compugen of therapeutic peptide product candidates for three drug targets of interest to Pfizer.

The discovery process, which will be based on various Compugen discovery platforms and funded by Pfizer, is expected to take a few months, following which the predicted molecules will be synthesized and delivered to Pfizer.

(Worcester Polytechnic Institute) Researchers at Worcester Polytechnic Institute have developed a new model system to study fungal infections.

The system can be a powerful tool for screening potential drug targets for conditions like thrush, athlete's foot and vaginal yeast infections, which affect millions of people each year but are difficult to treat with existing medications.

Using the new model, the researchers also identified a gene that may be a promising target for a new anti-fungal drug.